全文获取类型
| 收费全文 | 2507篇 |
| 免费 | 573篇 |
| 国内免费 | 9篇 |
专业分类
| 耳鼻咽喉 | 38篇 |
| 儿科学 | 50篇 |
| 妇产科学 | 79篇 |
| 基础医学 | 325篇 |
| 口腔科学 | 72篇 |
| 临床医学 | 257篇 |
| 内科学 | 596篇 |
| 皮肤病学 | 66篇 |
| 神经病学 | 185篇 |
| 特种医学 | 81篇 |
| 外科学 | 414篇 |
| 综合类 | 109篇 |
| 一般理论 | 2篇 |
| 预防医学 | 180篇 |
| 眼科学 | 72篇 |
| 药学 | 172篇 |
| 中国医学 | 30篇 |
| 肿瘤学 | 361篇 |
出版年
| 2023年 | 17篇 |
| 2022年 | 15篇 |
| 2021年 | 101篇 |
| 2020年 | 101篇 |
| 2019年 | 143篇 |
| 2018年 | 133篇 |
| 2017年 | 145篇 |
| 2016年 | 139篇 |
| 2015年 | 183篇 |
| 2014年 | 169篇 |
| 2013年 | 197篇 |
| 2012年 | 166篇 |
| 2011年 | 163篇 |
| 2010年 | 138篇 |
| 2009年 | 132篇 |
| 2008年 | 119篇 |
| 2007年 | 110篇 |
| 2006年 | 93篇 |
| 2005年 | 94篇 |
| 2004年 | 90篇 |
| 2003年 | 73篇 |
| 2002年 | 73篇 |
| 2001年 | 52篇 |
| 2000年 | 43篇 |
| 1999年 | 32篇 |
| 1998年 | 17篇 |
| 1997年 | 9篇 |
| 1996年 | 11篇 |
| 1995年 | 15篇 |
| 1994年 | 16篇 |
| 1993年 | 22篇 |
| 1992年 | 16篇 |
| 1991年 | 22篇 |
| 1990年 | 22篇 |
| 1989年 | 12篇 |
| 1988年 | 16篇 |
| 1987年 | 20篇 |
| 1986年 | 17篇 |
| 1985年 | 21篇 |
| 1984年 | 14篇 |
| 1983年 | 11篇 |
| 1982年 | 7篇 |
| 1981年 | 7篇 |
| 1979年 | 10篇 |
| 1978年 | 9篇 |
| 1974年 | 13篇 |
| 1973年 | 7篇 |
| 1972年 | 7篇 |
| 1971年 | 17篇 |
| 1970年 | 5篇 |
排序方式： 共有3089条查询结果，搜索用时 15 毫秒
1.
Kow Chia Siang Ramachandram Dinesh Sangarran Hasan Syed Shahzad 《Journal of thrombosis and thrombolysis》2022,54(2):217-218
Journal of Thrombosis and Thrombolysis - 相似文献
2.
3.
4.
5.
6.
Caryn Wujanto Jeremy Tey David Chia Francis Ho Kiat Huat Ooi Alvin S. Wong Yu Yang Soon Keith Lim 《Journal of Geriatric Oncology》2019,10(2):292-297
Background
Muscle invasive bladder cancer (MIBC) is prevalent in the older patients, who are a vulnerable population with multiple co-morbidities and at increased risk of complications. Radical cystectomy is often not suitable, hence radical radiotherapy (RT) is an alternative option. We reviewed the outcomes of older patients treated with RT with or without concurrent chemotherapy (CRT) at our institution.Methods
We retrospectively reviewed patients aged 65?years and above treated with radical RT for MIBC at our institution between March 2002 to January 2017. Data was collected from institutional medical records and RT databases. The primary outcome was 2- and 5-year overall survival (OS), recurrence free survival (RFS), and toxicities. Univariate cox proportional hazard regression models were performed to identify independent factors with significant impact on survival.Results
We identified 45 patients (34 males, 11 females) with a median age of 77?years (range 65–95). All patients received maximal transurethral resection of the bladder tumour prior to RT. Median dose of total RT was 64?Gy (range 50–69.8?Gy). Twenty one patients (47%) received CRT. Planned treatment was completed in 42 (93.3%) patients. Median follow-up was 31?months (range 1–147?months). The 2- and 5-year OS was 64% and 44%, respectively. The 2- and 5-year RFS was 68% and 49%, respectively. Median RFS was 34?months (range 8–121?months). Median OS was 56?months (range 18–100?months). Univariate analysis showed that performance status (0–1 vs. 2–3; HR 2.7, 95% CI 1.07–6.8, p?=?0.035) and International Society of Geriatric Oncology (SIOG) group (≤2 vs. >2; HR 3.23, 95% CI 1.12–8.64, p?=?0.019) were significantly associated with increased hazard for death. One patient (2%) had grade 3 cystitis.Conclusion
Radical RT is well tolerated in older patients with MIBC. We report outcomes similar to published data. Older patients should be considered for curative treatment despite their age. However, careful selection is warranted as frail patients (PS ≥2; SIOG >2) may benefit less. 相似文献7.
8.
Jae Eun Choi Tyler Werbel Zhenping Wang Chia Chi Wu Tony L. Yaksh Anna Di Nardo 《Journal of dermatological science》2019,93(1):58-64
Background
Rosacea is a chronic inflammatory skin condition whose etiology has been linked to mast cells and the antimicrobial peptide cathelicidin LL-37. Individuals with refractory disease have demonstrated clinical benefit with periodic injections of onabotulinum toxin, but the mechanism of action is unknown.Objectives
To investigate the molecular mechanism by which botulinum toxin improves rosacea lesions.Methods
Primary human and murine mast cells were pretreated with onabotulinum toxin A or B or control. Mast cell degranulation was evaluated by β-hexosaminidase activity. Expression of botulinum toxin receptor Sv2 was measured by qPCR. The presence of SNAP-25 and VAMP2 was established by immunofluorescence. In vivo rosacea model was established by intradermally injecting LL-37 with or without onabotulinum toxin A pretreatment. Mast cell degranulation was assessed in vivo by histologic counts. Rosacea biomarkers were analyzed by qPCR of mouse skin sections.Results
Onabotulinum toxin A and B inhibited compound 48/80-induced degranulation of both human and murine mast cells. Expression of Sv2 was established in mouse mast cells. Onabotulinum toxin A and B increased cleaved SNAP-25 and decreased VAMP2 staining in mast cells respectively. In mice, injection of onabotulinum toxin A significantly reduced LL-37-induced skin erythema, mast cell degranulation, and mRNA expression of rosacea biomarkers.Conclusions
These findings suggest that onabotulinum toxin reduces rosacea-associated skin inflammation by directly inhibiting mast cell degranulation. Periodic applications of onabotulinum toxin may be an effective therapy for refractory rosacea and deserves further study. 相似文献9.
10.